Julio Pimentel

Title(s)Postdoctoral Scholar, Pharmacology
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
ORCID ORCID Icon0000-0003-3475-5244 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Wayne State University School of Medicine , Detroit, MIPhD06/2023Oncology
    Harvard Medical School, Boston, MAPostgrad08/2018Translational Medicine
    University of Miami Miller School of Medicine, Miami, FLMSCTI07/2018Clinical Research
    California State University Stanislaus , Turlock, CABS12/2014Biological Sciences (Molecular Biology)
    Collapse Awards and Honors
    University of California, San Diego 2023  - 2025IRACDA Fellow
    University of California San Diego2023  - 2025NHLBI Diversity Supplement Award
    United States White House 2023Congratulatory letter from US President Joe Biden
    University of Miami Miller School of Medicine 2023Med’Canes Spring 2024 newsletter as an alumni feature.
    University of California, Irvine 2024University of California, Irvine Training Fellowship in Cancer Systems Biology

    Collapse Overview 
    Collapse Overview
    Dr. Julio M. Pimentel is a K12 NHLBI-funded postdoctoral scholar in the Department of Pharmacology at the University of California, San Diego School of Medicine (UCSDSM). He is also a candidate for assistant professor through the Institutional Research Academic Career Development Award (IRACDA) Program. Dr. Pimentel is a nationally recognized cancer researcher who has garnered numerous accolades for his work with his former PhD adviser, Dr. Gen Sheng Wu, on a novel non-canonical role for PD-L1 in TRAIL resistance in triple-negative breast cancer. Among his other awards are official recognition from US President Donald Trump and Joe Biden, the Governor of Michigan Gretchen Whitmer, as well as being awarded a 40 Under 40 and National Latino Leader twice. Dr. Pimentel researches the underlying mechanisms that impart therapeutic resistance in cancers, particularly those associated with vascular inflammation, as well as evasion of apoptosis and immunosurveillance. His current mentor is Dr. JoAnn Trejo, a member of the National Academy of Medicine, Senior Assistant Vice Chancellor for Health Sciences Faculty Affairs, and UCSD Professor.
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ubiquitin-driven G Protein-Coupled Receptor Inflammatory Signaling at the Endosome. 2024. Cheng N, Pimentel J.M, Trejo J. View Publication.
    2. American Journal of Cancer Research. The role of the immune response and inflammatory pathways in TNF-related apoptosis-inducing ligand (TRAIL) resistance in triple-negative breast cancer cells. 2023; 10(13). JM Pimentel, JY Zhou, GS Wu. View Publication.
    3. The mechanisms of TRAIL resistance in triple-negative breast cancer. 2023. Pimentel JM. . View Publication.
    4. Molecular Carcinogenesis. Cover Image. 2023; 62(2). Pimentel JM, Zhou, J.-Y. and Wu, G.S. View Publication.
    5. The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer. Cancers (Basel). 2023 May 13; 15(10). Pimentel JM, Zhou JY, Wu GS. PMID: 37345089; PMCID: PMC10216286.
      View in: PubMed   Mentions: 8  
    6. Regulation of programmed death ligand 1 (PD-L1) expression by TNF-related apoptosis-inducing ligand (TRAIL) in triple-negative breast cancer cells. Mol Carcinog. 2023 02; 62(2):135-144. Pimentel JM, Zhou JY, Wu GS. PMID: 36239572; PMCID: PMC10015553.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    7. Frontiers in Oncology. Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance. 2022; 12. Uddin MH, Zhou JY, Pimentel J, Patrick SM, Kim S, Shekhar MP, Wu GS. View Publication.
    8. Targeting PP2A inhibits the growth of triple-negative breast cancer cells. Cell Cycle. 2020 03; 19(5):592-600. Uddin MH, Pimentel JM, Chatterjee M, Allen JE, Zhuang Z, Wu GS. PMID: 32011210; PMCID: PMC7100985.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    9. Cancer research (Chicago, Ill.),. Abstract 5264: Metabolic reprogramming with β-alanine to overcome chemotherapy resistance in pancreatic cancer. 2019; 79:5624-5624. Danny Yakoub, Smitha T. Totiger, Alexandra Moran, Sujit Suwal, Julio Pimentel, Lauren O'Donell, Jamie Walls, Nagaraj Nagathihalli and Nipun Merchant. View Publication.
    10. Semantic Scholar. Characterizing and Detecting How Protein Fragments Pass Through the Intestinal Epithelial Layer With Emphasis on the Absorption of Collagen ' s Fragments. 2014. Pimentel JM, & Stone K. View Publication.